桂枝茯苓丸加减联合米非司酮治疗血瘀型子宫肌瘤临床观察

Clinical Observation of Modified Guizhi Fuling Pills Combined with Mifepristone in Treatment of Blood-stasis Type of Hysteromyoma

目的:观察桂枝茯苓丸加减与米非司酮联合治疗血瘀型子宫肌瘤的临床应用效果。方法:选取本院2015年1月—2016年12月收治的血瘀型子宫肌瘤患者90例,根据随机数字表法分为对照组及观察组,各45例。对照组单用米非司酮,观察组在对照组基础上加用桂枝茯苓丸加减,观察比较两组临床疗效、子宫肌瘤体积、子宫体积及用药安全性。结果:观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05);治疗后,观察组肌瘤体积及子宫体积均小于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:血瘀型子宫肌瘤患者在使用米非司酮基础上加用桂枝茯苓丸加减治疗,可有效促进患者肌瘤体积及子宫体积显著缩小,不会增加患者用药不良反应,临床疗效显著,用药安全性好。

Objective To observe the clinical application effects of modified Guizhi Fuling pills combined with mifepristone in treatment of bloodstasistype of hysteromyoma. Methods： 90 patients with blood-stasis type of hysteromyoma in our hospital from January 2015 to December 2016 wereselected, and they were divided into control group and observation group by random number table, 45 cases in each. Control group was treated withonly mifepristone, observation group was additionally treated with modified Guizhi Fuling pills on the base of control group. The clinical efficacy,volume of hysteromyoma, uterine volume and safety of medication of two groups were compared and observed. Results： The total effective rate ofobservation group was higher than that of control group （P〈0.05）; After treatment, the volume of hysteromyoma and uterine volume of observationgroup were smaller than those of control group （P〈0.05）; There was no statistical difference in the incidence of adverse reactions between two groups（P〉0.05）. Conclusion： Modified Guizhi Fuling pills combined with mifepristone in treatment of blood-stasis type of hysteromyoma can effectivelydecrease volume of hysteromyoma and uterine volume with no adverse reaction of medication. So it achieve significant clinical efficacy with goodmedication safety.